Our in vitro study confirmed that empagliflozin reduced the activation of NLRP3 and the expression of pyroptosis-related inflammasomes in pancreatic β cells under a high glucose environment, suggesting that the NLRP3/caspase-1/GSDMD pathway may be a potential therapeutic target for diabetes. This evidence concerns the gene CASP1 and diabetes mellitus.